Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04655586 · ClinicalTrials.gov registry record · Phase 2
Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19
A Phase 2 study, sponsored by ARCA Biopharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT04655586 is a Phase 2 study that has completed, run by ARCA Biopharma. The registered enrollment target is 160 participants.
The verdict
NCT04655586, a Phase 2 study, has completed, sponsored by ARCA Biopharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
Sequential randomized, multicenter, active comparator study to evaluate the hypothesis that rNAPc2 (AB201), a novel, potent and highly selective tissue factor inhibitor with anticoagulant, anti-inflammatory and potential antiviral properties, shortens time to recovery compared to heparin in hospitalized patients with COVID-19 and elevated D-dimer levels.
Interventions
- DRUG Heparin
- DRUG rNAPc2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2020-12-10 |
| Est. Completion | 2022-03-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04655586
The ClinicalTrials.gov registry entry for NCT04655586 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ARCA Biopharma, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Heparin is the first listed.
NCT04655586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04655586 about?
NCT04655586 is a clinical study titled "Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19". Sequential randomized, multicenter, active comparator study to evaluate the hypothesis that rNAPc2 (AB201), a novel, potent and highly selective tissue factor inhibitor with anticoagulant, anti-inflammatory and potential antiviral properties, shortens time to recovery compared to heparin in hospital...
What is the current status of trial NCT04655586?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2020-12-10. Estimated completion is 2022-03-07.
What interventions are being tested in trial NCT04655586?
The interventions under investigation include: Heparin (DRUG), rNAPc2 (DRUG).
Who is sponsoring clinical trial NCT04655586?
This trial is sponsored by ARCA Biopharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.